Hong Kong · Delayed Price · Currency is HKD Vigonvita Life Sciences Statistics
Total Valuation
HKG:2630 has a market cap or net worth of HKD 13.72 billion. The enterprise value is 14.17 billion.
| Market Cap | 13.72B |
| Enterprise Value | 14.17B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2630 has 167.60 million shares outstanding.
| Current Share Class | 66.68M |
| Shares Outstanding | 167.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 63.04% |
| Owned by Institutions (%) | 0.62% |
| Float | 42.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,089.47 |
| PB Ratio | 91.83 |
| P/TBV Ratio | 134.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -62.99 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -71.39 |
Financial Position
The company has a current ratio of 0.49, with a Debt / Equity ratio of 2.97.
| Current Ratio | 0.49 |
| Quick Ratio | 0.46 |
| Debt / Equity | 2.97 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.23 |
| Interest Coverage | -12.60 |
Financial Efficiency
Return on equity (ROE) is -132.51% and return on invested capital (ROIC) is -23.88%.
| Return on Equity (ROE) | -132.51% |
| Return on Assets (ROA) | -18.16% |
| Return on Invested Capital (ROIC) | -23.88% |
| Return on Capital Employed (ROCE) | -50.44% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | 1.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 54.97 |
| Average Volume (20 Days) | 116,622 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2630 had revenue of HKD 12.59 million and -224.97 million in losses. Loss per share was -1.55.
| Revenue | 12.59M |
| Gross Profit | 3.71M |
| Operating Income | -216.73M |
| Pretax Income | -231.61M |
| Net Income | -224.97M |
| EBITDA | -194.99M |
| EBIT | -216.73M |
| Loss Per Share | -1.55 |
Balance Sheet
The company has 129.13 million in cash and 443.17 million in debt, giving a net cash position of -314.04 million or -1.87 per share.
| Cash & Cash Equivalents | 129.13M |
| Total Debt | 443.17M |
| Net Cash | -314.04M |
| Net Cash Per Share | -1.87 |
| Equity (Book Value) | 149.38M |
| Book Value Per Share | 24.10 |
| Working Capital | -173.24M |
Cash Flow
In the last 12 months, operating cash flow was -115.84 million and capital expenditures -82.66 million, giving a free cash flow of -198.50 million.
| Operating Cash Flow | -115.84M |
| Capital Expenditures | -82.66M |
| Free Cash Flow | -198.50M |
| FCF Per Share | -1.18 |
Margins
| Gross Margin | 29.47% |
| Operating Margin | -1,721.30% |
| Pretax Margin | -1,839.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:2630 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1.64% |
| FCF Yield | -1.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HKG:2630 has an Altman Z-Score of -1.59 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.59 |
| Piotroski F-Score | 1 |